The dedicated, industry-focused summit optimizing clinical translation and trial design to drive the targeting of the complement inhibitors in rare and common disease indications.

The hotly anticipated 3rd Complement-based Drug Development Summit will be returning to Boston this November!

Join 150+ senior level complement experts from pharma, biotech and leading research institutions who are all working towards the same goal … to achieve clinical approval of effective complement inhibitors in rare and common disease indications.

The Complement-based Drug Development Summit provides a platform to share cutting edge data, understand the current clinical landscape and gain feedback from the industry on the right pathways and indications to target to ensure clinical success.

As the number of companies pursuing complement-based therapeutics is growing with rapidly expanding pipelines, the field is set to explode! The time has come to seize the therapeutic opportunity of complement inhibition, not only in rare disorders but also for more common disease indications. This meeting highlights the clinical developments of druggable complement targets from C5 and beyond.

Don’t miss out on your chance to network with the industry leaders, explore methods to improve clinical trial design to manage potential safety risks and identify translatable biomarkers to ensure successful drug approval.

With Alexion, Ra Pharma, Genentech & many more in the mix, will you be there too? Register your interest now!

“Great conference. Very organized and well run. A great range of presentation topics and very informative”

The Atypical HUS Foundation

“There was a well balanced mix of speakers representing early and late drug development efforts and approaches that have worked and ones that have failed. We often only hear the success stories, but one can learn maybe even more from the failures.”